Dysregulated expression of SKP2 and its role in hematological malignancies

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• S-phase kinase-associated protein 2 (SKP2) is an F-box protein crucial for the SCF E3 ligase complex.
• SKP2 regulates cell cycle progression by targeting p27 and p21 for degradation.
• Elevated SKP2 levels correlate with adverse outcomes in hematological malignancies.

Purpose of the Study:

• To review recent findings on the role of SKP2 in hematological malignancy pathogenesis.
• To highlight SKP2 as a potential therapeutic target in these cancers.

Main Methods:

• Literature review of studies investigating SKP2 function.
• Analysis of SKP2's role in cell cycle regulation and protein degradation.
• Examination of clinical data linking SKP2 to cancer outcomes.

Main Results:

• SKP2 promotes oncogenesis by reducing levels of cell cycle inhibitors p27 and p21.
• Loss of p27 due to SKP2 activity is linked to poor prognosis in hematological cancers.
• SKP2 is established as an oncogene in various cancer types.

Conclusions:

• SKP2 plays a significant role in the development and progression of hematological malignancies.
• Targeting SKP2 represents a viable therapeutic strategy for treating these cancers.